Gilead Sciences (GILD) Stock Research

Thursday

Gilead files automatic mixed securities shelf

GILD

Aug 6, 5:08 PM

Wednesday

Gilead price target lowered by $6 at Truist, here's why

GILD

Aug 5, 8:43 AM

Gilead price target raised by $3 at RBC Capital, here's why

GILD

Aug 5, 7:41 AM

Tuesday

Gilead raises FY26 EPS view to (65c)-(30c) from ($1.05)-(65c), consensus (75c)

GILD

Aug 4, 4:03 PM

Gilead reports Q2 adjusted EPS ($6.75), consensus ($7.25)

GILD

Aug 4, 4:02 PM

Monday

Gilead update on California ruling removes an overhang, says UBS

GILD

Aug 3, 3:31 PM

Over a week ago

Gilead price target lowered by $10 at Barclays, here's why

GILD

Jul 29, 5:07 AM

Gilead price target lowered by $1 at Morgan Stanley, here's why

GILD

Jul 27, 8:07 AM

Gilead's Trodelvy plus Merck's Keytruda recommended by CHMP in breast cancer

Jul 24, 6:30 AM

Gilead to present new HIV research at AIDS 2026

GILD

Jul 21, 10:06 AM

Gilead, Merck report 'high' rates of virologic suppression in ISLEND trials

Jul 21, 10:02 AM

Gilead downgraded at Leerink on long-term headwinds to HIV PrEP expansion

GILD

Jul 20, 4:21 PM

Leerink gets more bearish on Gilead, downgrades shares

GILD

Jul 20, 4:18 PM

Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

Jul 10, 5:29 AM

Citizens biotech analysts hold an analyst/industry conference call

Jul 9, 4:55 AM

Gilead price target lowered by $2 at Morgan Stanley, here's why

GILD

Jul 8, 7:38 AM

Early notable gainers among liquid option names on July 7th

Jul 7, 9:55 AM

Gilead price target lowered by $1 at Truist, here's why

GILD

Jul 7, 9:12 AM

Gilead price target lowered by $2 at RBC Capital, here's why

GILD

Jul 7, 7:20 AM

What You Missed On Wall Street On Monday

+27

Jul 6, 4:20 PM

Citizens biotech analyst holds an analyst/industry conference call

Jul 6, 2:30 PM

Midday Fly By: SK Hynix targets U.S. listing, Lockheed to acquire Ultra Maritime

+28

Jul 6, 1:20 PM

Okta upgraded, Datadog downgraded: Wall Street's top analyst calls

+26

Jul 6, 9:47 AM

Gilead just upgraded at HSBC, here's why

GILD

Jul 6, 5:41 AM

Dominant HIV Franchise: Gilead holds a leading position in the HIV treatment and prevention market, with highly effective and convenient regimens, providing a stable and substantial revenue base.

Robust Research & Development Pipeline: Consistent investment in R&D leads to a pipeline of potential new drugs across various therapeutic areas, particularly in oncology, antivirals, and inflammation, driving future growth.

Strong Intellectual Property Portfolio: A vast array of patents protects its existing blockbuster drugs and pipeline assets, ensuring market exclusivity and revenue generation for extended periods.

Patent Expirations and Generic Competition: Gilead's key blockbuster drugs face upcoming patent expirations, particularly within its established HIV franchise, which will lead to significant revenue declines due to generic market entry and increased competition.

Clinical Trial Failures: New drug candidates in Gilead's pipeline might fail to meet primary endpoints in clinical trials or demonstrate inadequate safety profiles, leading to substantial R&D write-offs, delayed market entry, and potential reputational damage.

Intense Market Competition: Gilead faces aggressive competition from other pharmaceutical and biotechnology companies across its core therapeutic areas, including HIV, oncology, and inflammation, potentially eroding market share for existing products and making new product launches challenging.

Charts

Dominant HIV Franchise: Gilead holds a leading position in the HIV treatment and prevention market, with highly effective and convenient regimens, providing a stable and substantial revenue base.

Strong Intellectual Property Portfolio: A vast array of patents protects its existing blockbuster drugs and pipeline assets, ensuring market exclusivity and revenue generation for extended periods.